- Home
- OKYO vs FATE Comparison
OKYO vs FATE Comparison
Compare OKYO & FATE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OKYO
- FATE
- Stock Information
- Founded
- OKYO 2007
- FATE 2007
- Country
- OKYO United Kingdom
- FATE United States
- Employees
- OKYO N/A
- FATE N/A
- Industry
- OKYO Biotechnology: Biological Products (No Diagnostic Substances)
- FATE Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- OKYO Health Care
- FATE Health Care
- Exchange
- OKYO Nasdaq
- FATE Nasdaq
- Market Cap
- OKYO 97.8M
- FATE 116.5M
- IPO Year
- OKYO 2022
- FATE 2013
- Fundamental
- Price
- OKYO $2.22
- FATE $0.99
- Analyst Decision
- OKYO Strong Buy
- FATE Buy
- Analyst Count
- OKYO 1
- FATE 7
- Target Price
- OKYO $7.00
- FATE $3.92
- AVG Volume (30 Days)
- OKYO 136.7K
- FATE 2.2M
- Earning Date
- OKYO 07-18-2025
- FATE 11-13-2025
- Dividend Yield
- OKYO N/A
- FATE N/A
- EPS Growth
- OKYO N/A
- FATE N/A
- EPS
- OKYO N/A
- FATE N/A
- Revenue
- OKYO N/A
- FATE $7,137,000.00
- Revenue This Year
- OKYO N/A
- FATE N/A
- Revenue Next Year
- OKYO N/A
- FATE N/A
- P/E Ratio
- OKYO N/A
- FATE N/A
- Revenue Growth
- OKYO N/A
- FATE N/A
- 52 Week Low
- OKYO $0.90
- FATE $0.66
- 52 Week High
- OKYO $3.35
- FATE $3.50
- Technical
- Relative Strength Index (RSI)
- OKYO 42.84
- FATE 35.33
- Support Level
- OKYO $2.33
- FATE $0.95
- Resistance Level
- OKYO $2.93
- FATE $1.16
- Average True Range (ATR)
- OKYO 0.22
- FATE 0.12
- MACD
- OKYO -0.05
- FATE -0.04
- Stochastic Oscillator
- OKYO 10.46
- FATE 6.70
About OKYO OKYO Pharma Limited
OKYO Pharma Ltd is a biopharmaceutical company. The company is developing therapeutics to improve the lives of patients with inflammatory eye diseases and chronic pain. It offers solutions for various diseases such as Dry Eye Disease, Non-infectious Anterior Uveitis, Allergenic Conjunctivitis, Chronic Pain, and Ocular Pain.
About FATE Fate Therapeutics Inc.
Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. It is engaged in the development of programmed cellular immunotherapies for cancer and autoimmune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.